Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05968703

Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease

The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is:

Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled.

Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford Neuroscience Health Center

Stanford, California, 94305, United States

Location status: Recruiting

Location contact

Study Coordinator

CONTACT

[email protected]

650-723-6709

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Parkinson's disease (PD)
  • Approved (or planning on) for subthalamic nucleus (STN) deep brain stimulation (DBS)
  • Willingness to withdraw from clinical medication regimen when necessary for research visits
  • Ability to provide informed consent

Exclusion criteria

  • Dementia
  • Unstable medical, psychiatric conditions including significant untreated depression, history of suicidal attempt, or current suicide ideation
  • History of seizures
  • Pregnant
  • Requires MRI
  • Unable to walk 100 feet without an assistive device

Treatment and study plan

Combined STN+NBM DBS

Device

This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)

Primary outcomes

  1. Adverse Events

    Time frame: From baseline to 1 year into treatment

    Any untoward medical occurrence that occurs during this study whether or not considered related to the study device, study procedures, or study requirements that is identified or worsens during the duration of the study

  2. Swing Time Coefficient of Variation

    Time frame: From baseline to 1 year into treatment

    Swing time variability will be measured using the dual force plates in the SIP task and IMUs for TBC. It is defined as the mean swing time coefficient of variation (CV) of both legs.

Secondary outcomes

  1. Percent Time Freezing

    Time frame: From baseline to 1 year into treatment

    Duration of freezing episodes during SIP will be measured using IMUs and force plates using a validated offline algorithm.

  2. Stride Time Coefficient of Variation

    Time frame: From baseline to 1 year into treatment

    Stride time coefficient of variation will be measured using the dual force plates in the SIP task and IMUs. Stride time coefficient of variation is defined as the mean stride time coefficient of variation (CV) of both legs. A greater stride time CV is indicative of less rhythmic gait/stepping.

  3. Shank Angular Velocity

    Time frame: From baseline to 1 year into treatment

    Shank angular velocity will be measured from IMUs work on the participant's leg/ankle. Reductions in this value are indicative of FOG and gait impairment.

  4. Tapping Speed

    Time frame: From baseline to 1 year into treatment

    The interstrike-interval of alternating tapping will be measured using an engineered piano keyboard. A higher interstrike-interval indicates slower tapping

  5. Tapping Rhythmicity

    Time frame: From baseline to 1 year into treatment

    The variability of the interstrike-interval of alternating tapping, as quantified by the coefficient of variation, will be measured using an engineered piano keyboard. A higher coefficient of variation indicates worse rhythmicity

  6. MDS-UPDRS III Score

    Time frame: From baseline to 1 year into treatment

    PD symptoms will be assessed clinically using the MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Section III. This is a motor examination to evaluate speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movement of hands, leg agility, arising from chair, posture, gait, freezing of gait, posture, body bradykinesia, and postural stability. Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132.

  7. SAT Score

    Time frame: From baseline to 1 year into treatment

    Each trial of the SAT will be categorized as a Hit (H), Miss (M), or False Alarm (FA). The SAT score is defined as ((H - FA) / [2× (H + FA) - (H + FA)2]), which ranges from - 1.0 (100% incorrect performance; all misses and false alarms) to +1.0 (100% correct performance; all hits and correct rejections).

  8. Percent False Positives

    Time frame: From baseline to 1 year into treatment

    The percent of false positives during the SAT.

  9. Percent Misses

    Time frame: From baseline to 1 year into treatment

    The percent of misses of total trials during the SAT

  10. Average + standard deviation of response time

    Time frame: From baseline to 1 year into treatment

    The average and standard deviation of the response time during the SAT.

  11. Goal-directed focus of attention

    Time frame: From baseline to 1 year into treatment

    Hit rate during the first minute in the no- distractor condition for the CTET.

  12. Sustained attention

    Time frame: From baseline to 1 year into treatment

    Hit rate change slope in no-distractor condition for the CTET.

  13. Distractibility

    Time frame: From baseline to 1 year into treatment

    Hit rate difference between no-distractor and distractor conditions for the CTET.

  14. Parkinson's Disease - Cognitive Rating Scale (PD-CRS)

    Time frame: From baseline to 1 year into treatment

    Cognitive scale composed of 9 tasks that assesses the full range of cognitive dysfunction in PD. It is a scale of 0 to 134, with 134 being the best score.

  15. Montreal Cognitive Assessment (MoCA)

    Time frame: From baseline to 1 year into treatment

    Total score to assess of this rapid screening test of different cognitive domains. It is a scale of 0 to 30, with 30 being the best score.

  16. Trails A

    Time frame: From baseline to 1 year into treatment

    The time it takes to complete the task and errors.

  17. Trails B

    Time frame: From baseline to 1 year into treatment

    The time it takes to complete the task and errors.

  18. Symbol Digit Modalities (SDMT) Oral and Written

    Time frame: From baseline to 1 year into treatment

    The summation of the number of correct substitutions within the 90 second interval.

  19. visual puzzles from the Wechsler Adult Intelligence Scale-IV (WAIS-IV)

    Time frame: From baseline to 1 year into treatment

    Percentile of performance on visual puzzles for participant's demographic.

  20. Judgement of Line Orientation

    Time frame: From baseline to 1 year into treatment

    Percentile of performance on judgement of line orientation for participant's demographic.

  21. Patient Health Questionnaire-9 (PHQ-9)

    Time frame: From baseline to 1 year into treatment

    Total score on questionnaire regarding participant's mood the last 2 weeks. The scale ranges from 0 to 27 with a score of 27 indicating the most severe symptoms.

  22. General Anxiety Disorder-7 (GAD-7)

    Time frame: From baseline to 1 year into treatment

    Total score on questionnaire regarding participant's anxiety the last two weeks.The scale ranges from 0 to 21 with a score of 21 indicating the most severe symptoms.

  23. MDS-UPDRS I

    Time frame: From baseline to 1 year into treatment

    Total score evaluating the non-motor aspects of experiences of daily living. It is a scale from 0 to 52 with 52 being the most severe symptoms.

  24. MDS-UPDRS II

    Time frame: From baseline to 1 year into treatment

    Total score evaluating the motor aspects of experiences of daily living. It is a scale from 0 to 52 with 52 being the most severe symptoms.

  25. MDS-UPDRS IV

    Time frame: From baseline to 1 year into treatment

    Total score of motor complications experienced by the participant. It is a scale from 0 to 24 with 24 being the most severe symptoms.

  26. Neuropsychiatric Inventory (NPI)

    Time frame: From baseline to 1 year into treatment

    Total score for symptom severity and distress via questionnaire. It is a scale from 0 to 60 with 60 indicating worse symptoms.

  27. Parkinson's Disease Questionnaire-39 (PDQ-39)

    Time frame: From baseline to 1 year into treatment

    Total score for Parkinson's disease-specific health related quality over the last month across 8 quality of life dimensions assessed via questionnaire. Score ranges from 0 to 100 with 100 indicating more symptoms and problems.

  28. Caregiver Burden Assessment

    Time frame: From baseline to 1 year into treatment

    Total score on caregiver self-report to assess the stress-levels of family caregivers. It is a scale from 0 to 88 with higher scores indicating greater or worse burden.

Study contacts

Contact information is provided by the study sponsor or research team.

Study Coordinator

CONTACT

[email protected]

650-723-6709

Sponsors and collaborators

Lead sponsor

Helen M. Bronte-Stewart

Other

Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Official study title

Neurostimulation of the Nucleus Basalis of Meynert for the Cognitive-Motor Syndrome in Parkinson's Disease

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 1, 2023
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.